doi: 10.3174/ajnr.A0963
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
American Journal of Neuroradiology 29:419-424, March 2008
© 2008 American Society of Neuroradiology
Review Article
Brain Tumor Imaging in Clinical Trials
a Stephen E. and Catherine Pappas Brain Tumor Imaging Research Program, Massachusetts General Hospital, Boston, Mass
b Division of Neuroradiology, Massachusetts General Hospital, Boston, Mass
c 3D Imaging Service, Massachusetts General Hospital, Boston, Mass
d Department of Radiology, Massachusetts General Hospital, Boston, Mass
e Neurology Service, Massachusetts General Hospital, Boston, Mass
f Harvard Medical School, Boston, Mass
Please address correspondence to John W. Henson, MD, Stephen E. and Catherine Pappas Brain Tumor Imaging Research Program, Massachusetts General Hospital, 55 Fruit St, Yawkey Nine East, Boston, MA 02114; e-mail: henson{at}helix.mgh.harvard.edu
SUMMARY: There are substantial challenges in the radiologic evaluation of tumor size during clinical trials, and it is important for neuroradiologists to have a firm understanding of these issues. This review will examine measurement approaches, response criteria, selection of lesions for measurement, technical imaging considerations, interval between tumor measurements and response confirmation, and validity of imaging as a measure of efficacy.